The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

Med Klinik I, Charité, Campus Benjamin Franklin, Berlin, Germany.
Annals of the rheumatic diseases (Impact Factor: 9.27). 03/2009; 68(6):777-83. DOI: 10.1136/ard.2009.108233
Source: PubMed

ABSTRACT To validate and refine two sets of candidate criteria for the classification/diagnosis of axial spondyloarthritis (SpA).
All Assessment of SpondyloArthritis international Society (ASAS) members were invited to include consecutively new patients with chronic (> or =3 months) back pain of unknown origin that began before 45 years of age. The candidate criteria were first tested in the entire cohort of 649 patients from 25 centres, and then refined in a random selection of 40% of cases and thereafter validated in the remaining 60%.
Upon diagnostic work-up, axial SpA was diagnosed in 60.2% of the cohort. Of these, 70% did not fulfil modified New York criteria and, therefore, were classified as having "non-radiographic" axial SpA. Refinement of the candidate criteria resulted in new ASAS classification criteria that are defined as: the presence of sacroiliitis by radiography or by magnetic resonance imaging (MRI) plus at least one SpA feature ("imaging arm") or the presence of HLA-B27 plus at least two SpA features ("clinical arm"). The sensitivity and specificity of the entire set of the new criteria were 82.9% and 84.4%, and for the imaging arm alone 66.2% and 97.3%, respectively. The specificity of the new criteria was much better than that of the European Spondylarthropathy Study Group criteria modified for MRI (sensitivity 85.1%, specificity 65.1%) and slightly better than that of the modified Amor criteria (sensitivity 82.9, specificity 77.5%).
The new ASAS classification criteria for axial SpA can reliably classify patients for clinical studies and may help rheumatologists in clinical practice in diagnosing axial SpA in those with chronic back pain. Trial registration number: NCT00328068.

Download full-text


Available from: Eduardo Collantes-Estevez, Jun 18, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ankylosing spondylitis (AS) is presented with axial and peripheral articular involvement. Uveitis is a severe and rather specific manifestation of AS. Biologics targeting tumor necrosis factor (TNF) α are effective on both articular and ocular manifestations of disease. The occurrence of uveitis in patients that never had eye involvement or the relapse of uveitis is described during anti-TNF α treatment. The frequency of these events is slightly higher during therapy with etanercept. The available TNF α blockers show different pharmacokinetics and pharmacodynamics yielding different biological effects. There is an ongoing debate whether uveitis during anti-TNF α has to be considered as paradoxical effect or an inadequate response to therapy. Here, we present a case report and review what the evidences for the two hypotheses are.
    Case Reports in Medicine 06/2014; 2014:471319. DOI:10.1155/2014/471319
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The management of spondyloarthritis is challenging and has changed with the development of new concepts and treatments. To develop practice guidelines for the everyday management of patients with spondyloarthritis (including psoriatic arthritis), by updating previous national and international recommendations, based on a review of recently published data. A task force and a multidisciplinary literature review group were established. The task force identified the issues that remained unresolved. Based on existing recommendations and recent publications, the task force developed practice guidelines, which were revised by the literature review group and graded according to AGREE. Practice guidelines for the management of spondyloarthritis are reported. After a review of the general diagnostic principles, 30 practice guidelines are given: 5 on general principles, 4 on the management strategy, 5 on non-pharmacological treatments, 7 on conventional pharmacological treatments, 6 on biotherapies, and 3 on surgical treatments and follow-up. The updated practice guidelines reported here constitute a global framework that can guide physicians in the everyday management of spondyloarthritis.
    Joint, bone, spine: revue du rhumatisme 01/2014; 81(1). DOI:10.1016/j.jbspin.2013.12.002 · 3.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective. To assess the clinical utility of repeat sacroiliac joint computed tomography (CT) in sacroiliitis by assessing the proportion of patients changing from normal to pathologic at CT and to which degree there is progression of established sacroiliitis at repeat CT. Methods. In a retrospective analysis of 334 patients (median age 34 years) with symptoms suggestive of inflammatory back pain, CT had been performed twice, in 47 of these thrice, and in eight patients four times. The studies were scored as normal, equivocal, unilateral sacroiliitis, or bilateral sacroiliitis. Results. There was no change in 331 of 389 repeat examinations. Ten patients (3.0%) had progressed from normal or equivocal to unilateral or bilateral sacroiliitis. Of 43 cases with sacroiliitis on the first study, 36 (83.7%) progressed markedly. Two normal cases had changed to equivocal. Eight equivocal cases were classified as normal on the repeat study. In further two patients, only small changes within the scoring grade equivocal were detected. Conclusions. CT is a valuable examination for diagnosis of sacroiliitis, but a repeated examination detects only a few additional cases of sacroiliitis. Most cases with already established sacroiliitis showed progression of disease.
    09/2013; 2013:659487. DOI:10.1155/2013/659487